Format

Send to

Choose Destination
Yale J Biol Med. 2013 Sep 20;86(3):343-58. eCollection 2013 Sep.

Strategies for dealing with missing data in clinical trials: from design to analysis.

Author information

1
Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut ; Yale Center for Analytical Sciences, New Haven, Connecticut.

Abstract

Randomized clinical trials are the gold standard for evaluating interventions as randomized assignment equalizes known and unknown characteristics between intervention groups. However, when participants miss visits, the ability to conduct an intent-to-treat analysis and draw conclusions about a causal link is compromised. As guidance to those performing clinical trials, this review is a non-technical overview of the consequences of missing data and a prescription for its treatment beyond the typical analytic approaches to the entire research process. Examples of bias from incorrect analysis with missing data and discussion of the advantages/disadvantages of analytic methods are given. As no single analysis is definitive when missing data occurs, strategies for its prevention throughout the course of a trial are presented. We aim to convey an appreciation for how missing data influences results and an understanding of the need for careful consideration of missing data during the design, planning, conduct, and analytic stages.

KEYWORDS:

MAR; MCAR; MNAR; clinical trial; intent to treat; missing data; study design

PMID:
24058309
PMCID:
PMC3767219
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center